Lisa-Tracker Extensions
Autoimmune Diseases
Key Facts
About Theradiag
Theradiag's mission is to advance personalized medicine through specialized diagnostic solutions for monitoring complex chronic diseases. The company has achieved a strong position in the European market for therapeutic drug monitoring of autoimmune diseases with its flagship Lisa-Tracker platform. Its strategy focuses on expanding its molecular diagnostics portfolio, forging strategic partnerships for commercial reach, and capitalizing on the growing demand for companion diagnostics in biotherapy management. As a publicly traded entity, Theradiag balances R&D investment with commercial execution to drive growth.
View full company profileTherapeutic Areas
Other Autoimmune Diseases Drugs
| Drug | Company | Phase |
|---|---|---|
| Humira (Adalimumab) Biosimilar | NeuClone | Early Preclinical |
| HBM7020 | Harbour BioMed | Discovery |
| R2006 | Harbour BioMed | Discovery |
| R7027 | Harbour BioMed | Discovery |
| ImmCelz™ Platform | Creative Medical Technology Holdings | Preclinical |
| Not specified in provided content | 3Sbio | Various |
| Gavocabtagene autoleucel | astellas | Phase 1/2 |
| TYK-101 | TYK Medicines | Phase 1 |
| HCB206 | HanchorBio | Preclinical |
| miR-124 Activator | Formation Bio | Phase 2 |
| Autologous Cell Therapy Collaboration | Lupagen | Preclinical |
| Autoimmune Diagnostics Leadership Initiative | Vibrant America Clinical Laboratory | Commercial |